Sinovac Evaluating Competing Take-Private Offers
This article was originally published in PharmAsia News
Beijing-based vaccines group Sinovac Biotech is evaluating two privatization proposals after competing offers from its CEO and an EV17 vaccine rival have emerged in recent days.
You may also be interested in...
Sinovac’s lengthy take-private process could be further delayed by the cloudy outlook for a potential relisting in China due to regulatory uncertainty and a tougher domestic environment, although the Chinese company’s rising competitiveness in the domestic vaccines market should help increase its valuation.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.